Endocrine Abstracts

JOINT23

Background: Metabolic syndrome (MetS) is a multifactorial condition linked to increased risk of cardiovascular disease and type 2 diabetes. Insulin resistance underpins its pathophysiology, yet traditional diagnostic methods are invasive and costly. The Single-Point Insulin Sensitivity Estimator (SPISE), a non-invasive index, offers a practical alternative for assessing insulin sensitivity. This systematic review and meta-analysis aim to evaluate the diagnostic accuracy of SPISE in detecting MetS.

Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines. We searched databases such as MEDLINE, Scopus, Web of Science, and Embase, focusing on studies evaluating SPISE’s screening accuracy for MetS. Eligible studies were observational, reporting mean SPISE values and its diagnostic performance. Meta-analyses were performed using Hedges’ g standardized mean differences (SMD) and pooled area under the curve (AUC) estimates.

Results: Seven studies comprising 12,919 participants were included. Individuals with MetS had significantly lower SPISE scores than controls (SMD = -0.94, 95% CI: -1.25 to -0.63). The pooled AUC for SPISE as a predictor of MetS was 0.86 (95% CI: 0.83 to 0.90), surpassing other insulin sensitivity indices like HOMA-IR and the triglyceride/HDL-C ratio. Meta-regression showed that systolic and diastolic blood pressure were potential sources of heterogeneity.

Conclusions: SPISE is a highly accurate and non-invasive tool for predicting MetS, potentially outperforming traditional indices like HOMA-IR. Its ease of use and diagnostic precision make it a valuable clinical screening tool, especially in diverse populations.